Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 9/20 | 0.41 |
| ▸ | BTK | Q06187 | 2/20 | 0.35 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.34 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18909617 | 0.89 | JAK3 (0.41) | JAK3BTKFGFR2KDRFGFR1 | |
| SCHEMBL17426143 | 0.85 | JAK3 (0.40) | JAK3BTKFGFR2KDRFGFR1 | |
| SCHEMBL18909694 | 0.85 | BTK (0.39) | JAK3BTK | |
| SCHEMBL18431345 | 0.85 | JAK3 (0.46) | JAK3BTKFGFR1EGFR | |
| SCHEMBL18331788 | 0.85 | JAK3 (0.46) | JAK3BTKFGFR1EGFR | |
| SCHEMBL18909691 | 0.85 | JAK3 (0.46) | JAK3BTKFGFR1EGFR | |
| SCHEMBL18904866 | 0.84 | JAK3 (0.39) | JAK3BTKFGFR2KDRFGFR1 | |
| SCHEMBL18909668 | 0.83 | CHRNB2 (0.38) | JAK3BTKFGFR2KDRFGFR1 | |
| SCHEMBL25977011 | 0.81 | JAK3 (0.37) | JAK3BTKFGFR2KDRFGFR1 | |
| SCHEMBL22631089 | 0.81 | JAK3 (0.37) | JAK3BTKFGFR2KDRFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170152264-A1 | AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2017-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152264-A1 | AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS | SSB, MAPKAPK5, BCL9 | JAK3 447/4885BTK 66/4885FGFR2 3618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.